Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Continuous Glucose Monitoring vs Fingerstick Monitoring for Hemoglobin A Control in Veterans.
Fed Pract
November 2024
Veterans Affairs Sioux Falls Health Care System, South Dakota.
Background: Patients with diabetes have traditionally been required to use fingerstick testing to self-monitor their glucose levels. However, continuous glucose monitors (CGMs) collect glucose readings throughout the day and display daily trends, which allow clinicians to individualize treatment to achieve hemoglobin A (HbA) goals and simplify medication regimens. While studies have shown that CGMs improve HbA levels compared to fingerstick testing, this research has focused on type 1 diabetes and excluded veterans and patients on insulin therapy.
View Article and Find Full Text PDFThe Impact of a Metformin Recall on Patient Hemoglobin A1c Levels at a VA Network.
Fed Pract
November 2024
Aptive Resources, Alexandria, Virginia.
Background: In May 2020, the US Food and Drug Administration (FDA) asked 5 pharmaceutical companies to voluntarily recall some formulations of metformin due to contamination. This observational study sought to provide insight changes in hemoglobin A (HbA) levels when veterans switched to alternative antihyperglycemic agents following the recall.
Methods: This study included veterans aged ≥ 18 years with type 2 diabetes who were receiving health care from Veterans Integrated Service Network 6 and had an active metformin sustained-action (SA) prescription as of June 1, 2020.
Background: In 2011, the Veterans Health Administration (VHA) undertook multidisciplinary efforts to improve care for patients with nonhealing foot ulcers and reduce leg amputation rates. This article examines the impact of interdisciplinary care for amputation prevention in the VHA.
Methods: The VHA patient population was characterized using internal registries.
Evaluating Use of Empagliflozin for Diabetes Management in Veterans With Chronic Kidney Disease.
Fed Pract
November 2024
Hershel "Woody" Williams Veterans Affairs Medical Center, Huntington, West Virginia.
Background: About 1 in 4 veterans have diabetes, and many also have chronic kidney disease (CKD). Empagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, is approved for the treatment of diabetes. The purpose of this study was to evaluate the effectiveness of empagliflozin on hemoglobin A (HbA) in patients with CKD.
View Article and Find Full Text PDFA Veteran Presenting With Fatigue and Weakness.
Fed Pract
October 2024
Veterans Affairs Boston Healthcare System, West Roxbury, Massachusetts.
: A 65-year-old male veteran presented to the Veterans Affairs Boston Healthcare System (VABHS) emergency department with progressive fatigue, dyspnea on exertion, lightheadedness, and falls over the last month. New bilateral lower extremity numbness up to his knees developed in the week prior to admission and prompted him to seek care. Additional history included 2 episodes of transient loss of consciousness resulting in falls and a week of diarrhea, which had resolved.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!